BioForest
Filter News
Found 19,138 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study
9/18/2020
Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline Significantly Fewer Overall Adverse Events Were Reported in Cytisinicline-Treated Subjects (p<0.001) Cytisinicline U.S. Phase 3 Trial Expected to Begin in Fourth Quarter 2020 [18-September-2020] SEATTLE and VANCOUVER,
-
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
9/18/2020
Seattle Genetics, Inc. and Astellas Pharma Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.
-
The Medical Device Epidemiology Network (MDEpiNet) and Medstreaming/M2S Establish Collaboration to Advance Real-World Evaluation of Medical Devices
9/18/2020
The Medical Device Epidemiology Network (MDEpiNet) and Medstreaming/M2S have established a strategic collaboration to advance real-world evaluation of medical devices.
-
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
9/18/2020
Astellas Pharma Inc. and Seattle Genetics, Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.
-
Athira Pharma Announces Pricing of Initial Public Offering
9/17/2020
Athira Pharma, Inc., (Nasdaq: ATHA) (“Athira”), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Athira
-
Proniras Corporation Announces National Institute on Drug Abuse (NIDA) Grant Award to Pursue Treatment for Opioid Withdrawal
9/17/2020
Proniras Corporation, a biotechnology company committed to the development of life saving therapeutic products, today announced that the company and its collaborator, Indiana University (IU) School of Medicine, have received a $12.3 million grant from the National Institute on Drug Abuse (NIDA) to support development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel, a
-
Magnolia Medical Appoints Former Becton Dickinson Senior Executives to Its Medical & Scientific Advisory Board
9/17/2020
Magnolia Medical Technologies, Inc. today announced the appointment of two healthcare safety veterans to its Medical & Scientific Advisory Board (MSAB) – Richard (Rick) M. Ivey, retired Worldwide Vice President of Research & Development for Becton Dickinson (BD) Life Sciences
-
BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials
9/17/2020
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has entered into an agreement with List Biological Laboratories, Inc. (“List Labs”) for the manufacture of its proprietary interferon alpha 2b for the treatment of COVID-19.
-
Prevencio Develops Highly Accurate, Artificial Intelligence-driven Blood Test for Kawasaki Disease
9/17/2020
HART KD test provides accurate diagnosis of critical childhood disease linked to COVID-19
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
-
Willamette Surgery Center Now Offering Highly Advanced Robotic-Arm Assisted Joint Replacement Procedures With Stryker's Mako System
9/16/2020
Willamette Surgery Center is the first ambulatory surgery center in Salem, Oregon to offer robotic-arm assisted total knee, partial knee and total hip replacements with Stryker's Mako System.
-
Seattle AVM Biotechnology announces second IND for AVM0703: clinical trial permitted to treat COVID-19 and Influenza ARDS with its "supercharged" version of dexamethasone
9/16/2020
AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients.
-
Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceutical Summit
9/16/2020
Pascal Biosciences Inc. (TSXV:PAS) oday Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements in each of Pascal's three cannabinoid programs. The title of his presentation is "Identifying and Validating Mechanism of Action In Vivo and In Vitro".
-
FUJIFILM Sonosite and the CHEST Foundation Partner for COVID-19 Research
9/15/2020
FUJIFILM Sonosite, Inc., the world leader in point-of-care ultrasound (POCUS) solutions, and the CHEST Foundation, the charitable foundation of the American College of Chest Physicians, today announced their joint grant in creating the CHEST Foundation Research Grant in Ultrasonography and COVID-19.
-
Curi Bio Announces Mantarray™ Platform for Analysis of 3D Engineered Muscle Tissues for Discovery of New Therapeutics
9/15/2020
Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the Mantarray™ platform for human-relevant 3D engineered muscle tissue (EMT) analysis. Curi’s Mantarray platform enables the discovery, safety, and efficacy testing of new therapeutics by providing parallel analysis
-
Curevo Vaccine Announces Robust Antibody Response Results of Phase I Clinical Trial of Investigational Vaccine for Shingles CRV-101
9/15/2020
Curevo Vaccine, a clinical stage biopharmaceutical company developing next generation vaccines for patients with infectious disease of global importance, today announced antibody response data from its completed Phase 1 study investigating the safety, tolerability, and immune system response of CRV-101 in several formulations.
-
Proven bone density screening and monitoring advancement enters U.S. market
9/15/2020
Echolight Medical, manufacturer of the innovative EchoS, which can diagnose osteoporosis and assess a person's risk for the disease within minutes without radiation, is broadening global operations with the opening of its United States headquarters in Seattle.
-
Gates Foundation's Annual Goalkeepers Report Shows COVID-19 Has Stalled 20 Years of Progress, Calls for Global Response to End the Pandemic
9/15/2020
Report shows how economic damage has reinforced inequities and derailed achievement of the UN Sustainable Development Goals; spotlights countries innovating to meet challenges